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Abstract
Hepatitis C Viral (HCV) infection in the injection drug user (IDU) population is a major medical concern.
Concurrent substance abuse, co-morbid mental health conditions, poor socioeconomic status and a
complex treatment protocol that is often incompatible with the life styles of IDUs combine to account for
poor uptake and completion of HCV treatment. This article discusses HCV antiviral treatment issues
relevant to IDUs chronically infected with this virus. The effect of non-injected substances of abuse on
treatment outcome is considered. Priority issues requiring research are discussed.
Background
Given its high incidence and prevalence, the complica-
tions of chronic hepatitis C virus (HCV) infection will
impact the morbidity and mortality of at-risk populations
in the developed world for the foreseeable future [1].
Those with substance abuse concerns, and particularly
injection drug users (IDUs), are at a greater risk of HCV
infection [2]. In North America, injection drug use
remains the primary risk factor for new and chronic infec-
tions. In Canada, injection drug use is estimated to
account for over half of all current HCV infections [3].
Approximately 55% of active and 49% of post injection
drug users are HCV infected [3]. Although therapy is avail-
able for HCV infection, there are multiple obstacles that
diminish the likelihood of past and present IDUs receiv-
ing combination interferon and ribavirin HCV treatment.
In this article, we discuss relevant HCV antiviral treatment
issues pertaining to IDUs chronically infected with HCV.
We additionally consider the effect of other substances of
abuse on treatment and priority issues requiring research.
Influence of substance use on natural history of HCV
Not all individuals with chronic HCV infection will
progress to advanced stages of fibrosis and end-stage liver
disease. During the initial period of evaluation of a HCV
infected patient, the physician formulates an impression
regarding the likelihood of poor outcome based on risk
factors for rapid progression (e.g. immune suppression,
alcohol use), physical examination, laboratory evaluation
and liver biopsy. Although the final decision to initiate
HCV antiviral therapy is made on a case-by-case basis,
treatment is strongly recommended for those having or at
least predicted to have more progressive disease.
The practice of drug injection is not known to directly
influence the rate of HCV progression despite the poten-
tial for multiple repeat exposures to various genotypes
and quasi-species. However, there are several factors asso-
ciated with injection drug use which may contribute to
accelerated progression [4]. Chief among these is excess
alcohol use which is generally defined as more that 50
grams of alcohol per day (i.e. approximately 3–4 beers per
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day). Concurrent excess alcohol consumption is found in
40% of active IDUs [5]. In our own clinic, we found that
75% of past injection drug users have a history of excess
alcohol use compared to 32% in those who acquired HCV
infection through other means (χ2, p < 0.001). In addition
to increasing risk behaviors [6], alcohol is well known to
accelerate the rate of hepatic fibrosis and reduce the time
to cirrhosis in HCV [7-9]. Clearly, concurrent alcohol use
in HCV is a factor predicting increased need for HCV ther-
apy but is also a factor limiting eligibility for access to
therapy. Furthermore, HCV antiviral therapy efficacy is
diminished in those engaging in excess alcohol use (see
below). As a primary measure, support for alcohol reduc-
tion and cessation is needed in those with HCV, irrespec-
tive of injection drug use.
Although not supported by strong evidence, it is plausible
that poor nutrition may play a role in influencing HCV
progression. Relative malnutrition and micronutrient
deficiency likely compromise the livers ability to control
chronic infection, contain inflammation and resorb
fibrotic material as it is produced [10]. Nutrition is often
substandard in substance users. Deficient food intake,
anorexia, nausea, vomiting, poor gastrointestinal absorp-
tion, altered metabolism and increased energetic expend-
iture contribute to a poor nutritional status in alcoholics
[11,12] and injection drug users [13].
Factors influencing treatment consideration
Psychiatric health
Psychiatric health is an important variable to consider
when determining the initiation of HCV antiviral therapy.
Those living with chronic HCV infection and those with
current or past injection drug use [14] have a heavy bur-
den of psychiatric illness [15-18]. In our clinic, depression
was identified in 62% of patients at initial evaluation
using the Center for Epidemiologic Studies of Depression
Scale (CES-D) [18,19]. To compound this problem, inter-
feron-based HCV therapies are well-known to increase the
frequency and severity of depression [20] and other psy-
chiatric illness [16]. The high frequency of depression
among HCV-infected patients is multifactoral. As in other
populations with chronic illnesses, such as cancer and dia-
betes, alcohol intake, smoking, and depression often co-
occur and influence mental well-being [21-24]. The inter-
relationships between the bio-psycho-social variables
within HCV-infected injection drug users are not fully
understood and deserve continued study. We and other
groups are evaluating the use of prophylactic antidepres-
sants in those initiating interferon-based HCV treatment
[25,26].
Socioeconomic challenges
There are several concrete obstacles to the successful deliv-
ery of HCV antiviral therapy to IDUs. Suitable shelter is
not always available and a lack of safe storage facilities for
HCV therapies negates successful adherence and treat-
ment success. The absence of refrigeration, which is
required for interferon storage between weekly dosing,
may compromise patients' ability to receive HCV therapy.
Poor attendance for outpatient clinical assessments is par-
tially explained by limited or cost-prohibitive transporta-
tion options.
Other obstacles to treatment are less tangible. Mistrust of
the medical community may influence patient willingness
to be assessed and initiation of HCV antiviral therapy.
This is, in part, fostered by multiple sources of inaccurate
or misinterpreted information pertaining to HCV disease
and treatment that can be found in the lay literature and
on the internet. Another contributing factor is the poor
treatment that many IDUs have experienced from law
enforcement services and medical personnel. The negative
view of IDUs among many in the medical community
[27] necessitates that medical personnel consider the
complex socioeconomic obstacles that placed the patient
in the risk category to begin with. This mistrust represents
an additional obstacle to the diagnosis and delivery of
health care, including HCV antiviral therapy. Recent
guidelines and commentaries have clearly stated that
ongoing substance abuse should not preclude considera-
tion for treatment [28,29]. This attitude has resonated
within the community of health care professionals deliv-
ering HCV care, which seem more willing to consider
treatment in this population, assuming that a reasonable
degree of stability in substance use has been achieved by
the patient.
A further concern for physicians dealing with HCV IDU
patients is the patient's exposure to physical and sexual
violence [30]. Populations at risk for physical and sexual
violence are at a heightened risk for exposure to HIV and
viral hepatitis infections. Although intervening on behalf
of patients by physicians is challenging, we should be
aware that this population is at an increased risk for vio-
lence and that initial intake discussions should specifi-
cally target issues of physical and sexual violence.
Therapeutic outcome
Influence of injection drug use
For patients no longer using injection drugs, the success of
therapy is determined by the same predictors (e.g. adher-
ence, genotype) as those without a history of injection
drug use. For those with active use, issues related to adher-
ence, tolerance and effectiveness, psychological health,
and risk of re-infection are important considerations.
In general, adherence to antimicrobial therapy is dimin-
ished in active drug users [31-33]. However, studies dem-
onstrate that adherence varies widely among IDU patientsHarm Reduction Journal 2006, 3:31 http://www.harmreductionjournal.com/content/3/1/31
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and can, in some cases, approach that of populations
without substance abuse [34-36]. Programs with special
expertise in providing care for drug users can increase
adherence rates to as high as 80% [37-42].
There is little conclusive data to suggest that HCV antiviral
therapy is tolerated less well or is less effective in those
with concurrent injection use. In fact, in one study, sus-
tained virological response rates comparable to other
HCV-treated populations were achieved despite relapses
to drug use in 80% of the patients receiving therapy [43].
This group attributed their success to providing multidis-
ciplinary care that included expertise in liver disease and
substance abuse management. Other studies replicate
these findings. A 29% sustained virological response rate
was achieved in a population of 66 methadone recipients
[44]. This cohort had a high level of concurrent psychiatric
illness (80%), concurrent alcohol use while on therapy
(20%) and one-third relapsed into illicit drugs use. Ther-
apy was effectively and safely delivered by provision of
mental health care and appropriate resources to stabilize
ongoing substance use.
Re-infection is often cited as justification to withhold
HCV antiviral treatment from those with ongoing injec-
tion drug use. Although there is a risk and documented
examples of have been cited [45], re-infection is a rare
occurrence. HCV is generally acquired early in the career
of an IDU as a result of inexperience and lack of knowl-
edge regarding safe injecting techniques. Most patients
presenting to clinic for therapy have a long history of
injection drug use and are therefore less likely to commit
the same errors in safe needle use as their junior counter-
parts. Of course, education and support for safe injection
practices is an important component of care delivery to
those treated for HCV infection. Support for safe injection
facilities, needle exchange programs and provision of
injection equipment have been demonstrated to reduce
infection rates [46-49]. It is reasonable to assume that this
benefit would extend to those who successfully clear HCV
with antiviral therapy.
Influence of alcohol on HCV treatment
Alcohol consumption impairs the efficacy of interferon-
based HCV therapy [50,51]. There are several ways in
which alcohol is thought to produce this negative influ-
ence on treatment outcomes. Most studies suggest that
excess alcohol consumption increases HCV RNA levels
[52-57]. In mice, alcohol consumption blunts HCV-spe-
cific T-helper and cytotoxic T lymphocytes response as
well as cytokine expression [58,59]. Furthermore,
decreased interferon-γ levels, resulting from alcohol-
induced dendritic cell dysfunction [59,60] likely influence
HCV RNA levels. Both HCV RNA level and immune status
predict sustained virologic response rates to interferon-
based HCV treatment.
Although ongoing controlled alcohol (or other substance
abuse) should not preclude HCV drug therapy [46], cessa-
tion of alcohol use should be emphasized as a highly ben-
eficial therapeutic intervention. Physicians are in an
optimal situation to encourage alcohol reduction strate-
gies and brief discussions with patients may reduce alco-
hol intake [61]. With successful alcohol reduction, liver
inflammation and fibrosis will be reduced, HCV RNA lev-
els will decline, and the probability of response to HCV
drug therapy will be increased. This intervention requires
sustained patient and physician commitment to alcohol
cessation programs and patience.
Other substances of concern
Influence of smoking and marijuana use
High rates of cigarette smoking have been reported among
HCV patients in Canada, Europe, and the Far East[18,62-
64]. In our own cohort, the rate of cigarette smoking
(63%) reported in HCV infection was much higher than
the Canadian national average rate of 24% [18,65]. Smok-
ing is also common among injection drug users [66].
Cigarette smoking has many known negative health con-
sequences [67] and has been consistently associated with
reduced health-related quality of life [18,67,68]. The neg-
ative physical effects of smoking have been found to be
more severe in those with chronic medical conditions,
including liver disease. In a cross-sectional study of 6095
individuals with HCV, cigarette smoking along with alco-
hol abuse were both independently associated with ele-
vated ALT levels [69]. Tobacco smoking has also been
linked to hepatocellular carcinoma [21,22] and increased
Knodell fibrosis [63]. Among Japanese patients with
chronic liver disease (67% were HCV positive), hepatocel-
lular carcinoma was higher for smokers and was inde-
pendent of alcohol use (Relative Risk 15.4) [22]. Smoking
may also increase histological activity in chronic HCV
patients irrespective of alcohol use [70]. These findings
justify further systematic assessment of the impact of
smoking on those living with chronic liver disease.
Cigarette smoking has been associated with clinically rel-
evant decrements in physical and mental health-related
quality of life in those chronically infected with HCV
[18,71]. Given that cigarette smoking is a modifiable
health behavior, these findings may have important clini-
cal implications. Smoking cessation interventions may
help improve health-related quality of life for those with
HCV-infection [72,73]. Further study of the effectiveness
of psychological and/or pharmacological treatments for
smoking cessation and relapse prevention, and the impactHarm Reduction Journal 2006, 3:31 http://www.harmreductionjournal.com/content/3/1/31
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of these interventions on HCV patients' long-term health-
related quality of life are justified.
The tar in marijuana contains similar carcinogens to those
found in tobacco cigarettes [74]. Furthermore, marijuana
smoking has been associated with increased risk of head
and neck cancer [74]. To be fair, patient testimony sug-
gests that marijuana many play a valuable role in attenu-
ating the many side effects associated with interferon and
ribavirin-based HCV treatment. In fact, treatment out-
comes have been reported to be improved in those using
marijuana compared to those not [44]. Future research on
the influence of marijuana smoking on liver disease pro-
gression, HCV health-related quality of life and HCV treat-
ment efficacy should be pursued.
Influence of HIV co-infection on HCV progression and 
treatment
As a result of common risk factors for exposure, HCV and
HIV are often found concurrently. The pace of HCV-
induced hepatic fibrosis is accelerated in those with HIV
co-infection [7,75]. As a result, the burden of end stage
liver disease and liver-related death is increased [76,77].
For these reasons, HCV treatment evaluation is essential
in those with HIV-HCV co-infection. The likelihood of
successfully clearing HCV infection with interferon and
ribavirin-based therapy is diminished in those with HIV
co-infection, even with well managed HIV disease [78,79].
Treatment side effects are not inconsequential but, in gen-
eral, not substantially more plentiful or severe in co-infec-
tion [78,79]. Traditionally, there have been concerns
pertaining to interactions between ribavirin and HIV
antiretrovirals [80,81]. As didanosine, stavudine and
zidovudine use diminish as safer alternates become avail-
able, concerns about nucleoside drug interactions with
ribavirin have diminished. It is clear that pegylated inter-
feron use in this immune compromised population does
not result in a greater risk of infectious complications or
HIV-defining opportunistic infections [78,82].
Research priorities
Investigation and validation of treatment strategies which
will improve adherence to viral hepatitis drug therapy are
required to ensure that individuals who use injection
drugs or other substances of abuse derive the maximal
possible benefits from current viral hepatitis therapies.
Given the wide spread use of medicinal marijuana in this
population, quantification of the benefits and negative
consequences of regular, long term use is mandatory. Rig-
orous evaluation of the safety, purported benefits and
effect on quality of life are required for the many alterna-
tive and herbal remedies used by those living with HCV.
Many patients seek alternative sources of health care for a
variety of reasons, including cultural relations, belief-sys-
tems, the concept of detoxifying their liver, and the poten-
tial therapeutic benefits of alternative therapies.
Acupuncture, a traditional Asian intervention, often used
for addiction and substance cravings, has been evaluated
in a number of randomized trials. The evidence, has how-
ever, shown consistently that acupuncture is ineffective in
addictive drug use [83,84]. A popular herbal medicine
used by patients with liver disorders, including HCV, is
Milk Thistle (Silybum marianum). Although the safety of
Milk Thistle is now largely established [85], the therapeu-
tic effectiveness is still uncertain. Some evidence suggests
that it has therapeutic effectiveness in hepatitis B/C in
reducing liver-related mortality. However, better quality
studies indicate this result is uncertain [86]. There are cur-
rently large trials enrolling HCV patients to determine
Milk Thistle's impact on HCV specific outcomes.
It is plausible that the course and outcome of HCV many
differ in those infected by injection drug use. Inoculum
size and frequency of exposure may perturb the viral-host
immune interaction. The poor nutrition status of injec-
tion drug uses may influence HCV pathogenesis and
response to therapy. Well-designed analyses of this issue,
which control for key confounders including alcohol use
and nutritional status would provide clarity.
The need to implement interventions to reduce the infec-
tion rate of HCV among IDUs is critical. Although ongo-
ing research is vital to ensure optimal application of
techniques to limit the spread of HCV in this high risk
group, this should not be used as an excuse to delay intro-
duction of practices which are now well known to be
effective) [46-49].
Conclusion
HCV infection in the IDU population is a major medical
concern, one that is likely to remain for the foreseeable
future. The difficulties of delivering current interferon-
based HCV treatment to this population are well known.
Co-morbid mental health concerns, concurrent substance
use and abuse, poor socioeconomic status, exposure to
violence and a treatment protocol that is often not com-
patible with the schedules of injection drug users combine
to account for poor uptake and completion of HCV treat-
ment. Moral and financial support from government for
this disenfranchised population would perhaps provide
the greatest impetus to allow for successful delivery of
HCV treatment to this population. In a more favorable cli-
mate, practices demonstrated to reduce harmful behavior
and effectively manage the above risk factors and co-mor-
bidities in the IDU population could produce improve-
ment in individual and population health. This, in turn
would make HCV drug treatment more accessible to a
larger proportion of those requiring therapy.Harm Reduction Journal 2006, 3:31 http://www.harmreductionjournal.com/content/3/1/31
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